14-year risk of all-cause mortality according to hypoglycaemic drug exposure in a general population

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Bérard, Emilie ^a   Bongard, Vanina ^a   Dallongeville, Jean ^b   Arveiler, Dominique ^c   Cottel, Dominique ^b   Wagner, Aline ^c   Ruidavets, Jean Bernard ^a   Ferrières, Jean ^a,d  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DRUG EXPOSURE; FEMALE; GLYCEMIC CONTROL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SMOKING; SURVIVAL RATE; TREATMENT INDICATION; DIABETES MELLITUS, TYPE 2; SURVIVAL;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84899691968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095671     Document Type: Article

References (20)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596.
2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559.
3. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, et al. (2000) Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 355:675-687. (Pubitemid 30107623)
4. Marques-Vidal P, Ruidavets JB, Amouyel P, Ducimetière P, Arveiler D, et al. (2004) Change in cardiovascular risk factors in France, 1985-1997. Eur J Epidemiol 19:25-32. (Pubitemid 38250050)
5. Centre de recherche en Epidémiologie et Santé des Populations (CESP), INSERM - Université Paris Sud (2012) Mise en oeuvre du décret no 98-37 autorisant l'accès aux données relatives au décès des personnes inscrites au Répertoire National d'Identification des Personnes Physiques (RNIPP) dans le cadre des recherches dans le domaine de la santé. Available: http://cesp.vjf.inserm.fr/svcd. Accessed 2013 Dec 30.
6. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) (1993) Arch Intern Med 153:154-183.
7. Friedewald WT, Levy RI, Fredrickson DS (1978) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502.
8. The expert committee on the diagnosis and classification of diabetes mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197.
9. Saurel-Cubizolles MJ, Chastang JF, Menvielle G, Leclerc A, Luce D, EDISC group (2009) Social inequalities in mortality by cause among men and women in France. J Epidemiol Community Health 63:197-202.
10. Cottel D, Dallongeville J, Wagner A, Ruidavets JB, Arveiler D, et al. (2000) The North-East-South gradient of coronary heart disease mortality and case fatality rates in France is consistent with a similar gradient in risk factor clusters. Eur J Epidemiol 16:317-322. (Pubitemid 30643109)
11. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, et al. (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169.
12. Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753-759.
13. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12:47-53.
14. Muis MJ, Bots ML, Grobbee DE, Stolk RP (2005) Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 22:118-126. (Pubitemid 40204316)
15. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005. (Pubitemid 30349423)
16. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, et al. (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441.
17. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050. (Pubitemid 39345873)
18. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258. (Pubitemid 44106500)
19. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
20. Machin D, Campbell MJ, Tan SB, Tan SH (2009) Sample size tables for clinical studies. Third Edition. Oxford: Wiley-Blackwell, page 101.